Rocket Lab, RTX, and Palantir: The Best SpaceX Alternatives for Investors Who Missed the IPO or Want Out

Rocket Lab disclosed a record launch contract that helped lift backlog above $2.2 billion, while Neutron remains on track for a Q4 2026 debut and a phased launch ramp. RTX reported a $271 billion backlog, including a $50 billion 20-year Patriot missile-defense contract, and Palantir’s Maven AI was made a formal Pentagon program of record alongside a $10 billion, decade-long U.S. Army agreement. The article is broadly constructive on aerospace and defense names, emphasizing durable contracted revenue and long-duration visibility.

Analysis

The market is increasingly rewarding aerospace names that have shifted from promise to contractual visibility. The important second-order effect is that backlog quality now matters more than headline launch cadence: RTX and PLTR are effectively turning government and defense budgets into annuity-like cash flow streams, while RKLB is trying to graduate from “optional future platform” to a multi-year manufacturing and launch franchise. That transition tends to compress financing risk and expand valuation multiples because the market stops pricing these businesses like binary tech bets and starts valuing them like long-duration industrials with embedded option value.

RKLB is the cleanest asymmetric setup, but the market is still likely underappreciating how much of the Neutron story is already being monetized before the first flight. The real catalyst is not the inaugural launch itself; it is the re-rating that follows evidence of launch rhythm plus spacecraft manufacturing attach rates, which can lift gross margin before vehicle scale is fully proven. The risk is a classic aerospace execution gap: any slip in late-2026 timing or early-ramp reliability would likely hit the stock harder than the size of the delay would imply, because the equity is trading on a compressed timeline to “prove it.”

RTX is the lower-beta compounding trade, but the more interesting angle is supply-chain scarcity. Missiles, engines, and sustainment capacity are all becoming bottlenecks, which means the winners are not just primes but also select sub-tier suppliers with proprietary content and multi-year pricing power. The contrarian risk is that the market may already be over-allocating credit for long-cycle defense visibility while underestimating margin pressure from labor, rework, and capex drag as RTX scales production.

PLTR remains the most controversial name because the stock is already priced as if government adoption is irreversible. The key debate is not whether the company has a durable moat inside defense, but whether the next leg of returns comes from budget expansion or commercial monetization leverage; if government becomes too dominant, multiple expansion can stall even as fundamentals improve. A more nuanced view is that a program-of-record designation reduces churn risk and should lower the discount rate applied to future revenue, but it also raises the bar for incremental surprise.

Key Decisions for Investors

• Long RKLB on any post-hype pullback over the next 2-6 weeks; target a 12-18 month hold into Neutron milestone checkpoints. Risk/reward is attractive if the market continues to pay for backlog conversion, but trim aggressively on any material schedule slip.
• Add RTX as a lower-volatility defense compounder for 6-12 months. Prefer buying weakness after broad sector rotations; the setup is less about upside surprise than durable cash flow with limited narrative risk.
• Maintain core long PLTR but hedge with shorter-dated upside sales or collars into earnings/contract headlines. The stock can keep compounding, but the biggest risk is multiple compression if growth becomes perceived as budget-dependent rather than category-expanding.
• Pair trade: long RKLB / short a basket of pre-revenue space names over 3-9 months. The market should continue rewarding companies with actual backlog, manufacturing content, and defense relationships over pure concept exposure.
• For risk-managed exposure, buy RTX and PLTR on 3-5% pullbacks rather than chasing strength. The thesis is durable, but near-term upside is likely more path-dependent than linear.